A premier developer of advanced robotic surgical systems that are transforming minimally invasive procedures globally with a focus on precision and surgeon empowerment.
Inspire Medical Systems offers compelling growth potential as its robotic platforms gain traction in cost-conscious ambulatory surgery centers, diversifying beyond traditional hospital markets. The company's strong profitability trajectory, with net income turning positive and expanding rapidly, suggests improving unit economics and pricing power. Strategic investments in R&D and software enhancements position the firm to maintain a technological edge against competitors in an increasingly digital healthcare landscape.
High levels of intangible assets and significant investment in research and development at $103.2M pose ongoing capital expenditure risks if new product launches underperform expectations. The company faces substantial competition from both established giants and low-cost generic alternatives that could erode margins on its premium robotic systems. Dependence on a single flagship product line creates concentration risk, especially given the long sales cycles required to secure large hospital contracts.
Inspire Medical Systems is a leading innovator in medical technology, specializing in advanced surgical systems like the da Vinci Xi that empower surgeons with enhanced visualization and precise control. The company serves global healthcare markets including hospitals, ambulatory surgery centers, and academic institutions through its flagship robotic surgical platforms. Its revenue growth reflects strong adoption of its high-end robotics solutions across diverse surgical specialties worldwide.
The company demonstrated a remarkable turnaround with net income surging to $145.4M in 2025 from a loss of $-21.2M the prior year, reflecting improved operational efficiency and strong product adoption. Revenue growth accelerated significantly, reaching $912.0M in 2025 after climbing from $407.9M in 2022, indicating robust market penetration. However, investors should note that cash flow from financing was negative at $-183.4M due to substantial share repurchases of $175.0M and other obligations.
The global medical robotics industry is experiencing rapid expansion driven by aging populations, rising healthcare costs, and the demand for minimally invasive procedures that reduce recovery times. Established players dominate the market with extensive service networks, but niche innovators are gaining ground through specialized applications and cost-effective platforms targeting outpatient settings. Regulatory approval processes remain stringent, creating high barriers to entry but also protecting incumbents from immediate price wars.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $407.9M | $624.8M | $802.8M | $912.0M |
| Cost of Revenue | $66.1M | $96.6M | $123.0M | $133.2M |
| Gross Profit | $341.7M | $528.2M | $679.8M | $778.8M |
| Operating Expenses | $389.3M | $568.5M | $643.7M | $727.8M |
| Operating Income | $-47.6M | $-40.3M | $36.1M | $51.0M |
| R&D | $68.6M | $116.5M | $114.1M | $103.2M |
| G&A | $320.7M | $452.0M | $529.6M | $624.6M |
| Stock-Based Comp | $52.0M | $82.5M | $116.0M | $130.3M |
| D&A | $1.9M | $2.8M | $6.5M | $14.0M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $3.3M | $20.4M | $22.4M | $14.7M |
| Interest Expense | $1.7M | $0 | — | — |
| Pre-Tax Income | $-44.3M | $-19.9M | $58.5M | $65.7M |
| Income Tax | $613.0K | $1.2M | $4.9M | $-79.7M |
| Continuing Ops | $-44.9M | $-21.2M | $53.5M | $145.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-44.9M | $-21.2M | $53.5M | $145.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-44.9M | $-21.2M | $53.5M | $145.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $530.0M | $593.7M | $630.8M | $583.7M |
| Cash & Equivalents | $441.6M | $185.5M | $150.2M | $104.8M |
| Marketable Securities | $9.8M | $274.8M | $295.4M | $203.5M |
| Accounts Receivable | $61.2M | $89.9M | $93.1M | $119.7M |
| Inventory | $11.9M | $33.9M | $80.1M | $145.3M |
| Other Current Assets | $5.5M | $9.6M | $12.1M | $10.4M |
| Long-Term Assets | $34.8M | $83.1M | $177.6M | $323.7M |
| PP&E (Net) | $17.2M | $40.0M | $71.9M | $97.9M |
| Operating Leases | $6.9M | $22.7M | $23.3M | $23.5M |
| LT Investments | $0 | $9.1M | $71.0M | $96.3M |
| Other LT Assets | $10.7M | $11.3M | $11.3M | $105.9M |
| Total Assets | $564.9M | $676.8M | $808.4M | $907.3M |
| Current Liabilities | $61.2M | $78.1M | $88.5M | $96.1M |
| Current Leases | $1.3M | $0 | $1.8M | $2.2M |
| Taxes Payable | — | — | $1.6M | $2.5M |
| Other Current Liab | $25.5M | $38.8M | $35.3M | $32.0M |
| Long-Term Liabilities | $7.7M | $26.2M | $30.2M | $30.1M |
| LT Operating Leases | $7.5M | $24.8M | $30.0M | $30.0M |
| Other LT Liab | $146.0K | $1.3M | $148.0K | $104.0K |
| Total Liabilities | $68.9M | $104.3M | $118.7M | $126.2M |
| Shareholders' Equity | $496.0M | $572.5M | $689.7M | $781.2M |
| Paid-In Capital | $820.3M | $917.1M | $981.0M | $927.2M |
| Retained Earnings | $-324.3M | $-345.4M | $-291.9M | $-146.5M |
| AOCI | $-86.0K | $800.0K | $536.0K | $464.0K |
| Total L&E | $564.9M | $676.8M | $808.4M | $907.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-44.9M | $-21.2M | $53.5M | $145.4M |
| Non-Cash Adjustments | $5.7M | $-27.4M | $12.1M | $-120.6M |
| Working Capital Changes | $50.8M | $73.2M | $64.6M | $92.1M |
| Cash from Operations | $11.6M | $24.7M | $130.2M | $117.0M |
| Capital Expenditures | $9.1M | $23.6M | $39.1M | $38.5M |
| Cash from Investing | $-19.6M | $-294.8M | $-113.1M | $21.4M |
| Debt Repayments | $24.5M | $0 | $0 | — |
| Share Buybacks | — | — | $75.0M | $175.0M |
| Cash from Financing | $235.1M | $13.9M | $-52.4M | $-183.4M |
| FX Effect | $75.0K | $164.0K | $-118.0K | $-310.0K |
| Net Change in Cash | $227.1M | $-256.1M | $-35.4M | $-45.3M |
| Beginning Cash | $214.5M | $441.6M | $185.5M | $150.2M |
| Ending Cash | $441.6M | $185.5M | $150.2M | $104.8M |
The company's revenue is primarily driven by the sale of its flagship robotic surgical platforms such as the da Vinci Xi, along with associated disposable instruments, reprocessing services, and software subscriptions. Additional streams include service contracts for existing installations, training programs for surgeons, and the growing market share in ambulatory surgery centers seeking cost-effective robotic solutions.
Regulatory hurdles in key markets like Europe and China could disrupt global expansion plans for its robotic platforms. Supply chain disruptions affecting the availability of specialized surgical instruments or rare earth materials used in robotics could impact production timelines. Intense competition from established players like Intuitive Surgical and emerging low-cost alternatives threatens market share and pricing power.
Inspire Medical Systems leverages a robust proprietary technology moat through its patented robotic hardware and intuitive user interface that reduces learning curves for surgeons. The company benefits from high switching costs due to extensive surgeon training ecosystems and long-term service contracts that create recurring revenue stability. Its strategic focus on expanding into ambulatory surgery centers provides a scalable growth vector against traditional hospital-based competitors.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.